The Netherlands, The Hague, 19th January 2024 — Affidea Group, the leading pan-European provider of integrated healthcare including advanced diagnostics, out-of-hospital services and Centres of Excellence, today announces the appointment of Frans van Houten as a non-executive Supervisory Board Member. A recognised visionary in healthcare innovation and technology sectors, Frans van Houten will leverage his leadership skills and insights to significantly enhance Affidea's aspirations for growth and digital innovation.

Frans van Houten spent nearly 30 years at Royal Philips and is highly regarded for his strategic insights. In his role as CEO, he transformed the organisation from a diversified conglomerate into a focused health technology solutions company. This transformation doubled Philips' organic growth and profitability. Additionally, Frans van Houten currently serves on Novartis' Board of Directors, contributing to one of the world's foremost pharmaceutical companies, and also advises the private equity sector.

Frans van Houten stated: “Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support. The company's longstanding dedication to enhancing every aspect of the care pathway and improving patient outcomes through technological innovation resonates with my own. My commitment is to the seamless integration of cutting-edge, patient-centric solutions that promise quality, personalised and efficient healthcare experiences throughout the care continuum. I look forward to collaborating with the Supervisory Board and management team to unlock Affidea's complete growth potential."

Michal Chalaczkiewicz, Chairman of Affidea’s Supervisory Board and Investment Partner at GBL, added: “We are delighted to welcome Frans van Houten to Affidea’s Supervisory Board, joining the other distinguished members. His appointment represents a significant addition, embodying GBL's commitment as a shareholder in Affidea. We are looking forward to working alongside Frans and leveraging his expertise as we build the future path of this exciting journey together with the teams at Affidea and GBL”.

Guy Blomfield, CEO of Affidea Group and Chairman of the Management Board, stated: “We warmly welcome Frans to our Supervisory Board. His expertise in pioneering innovative, connected and patient-focused solutions will be relevant to Affidea's strategic growth plans. His track record in digital transformations is particularly important. The company will benefit from his experience in standardising and optimising processes and data management, leading to optimal care pathways and, progressively, the adoption of AI solutions.”

More People on the Move